Brighton Jones LLC Grows Stock Holdings in Eli Lilly and Company $LLY

Brighton Jones LLC lifted its holdings in Eli Lilly and Company (NYSE:LLY) by 9.4% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 11,909 shares of the company’s stock after purchasing an additional 1,021 shares during the period. Brighton Jones LLC’s holdings in Eli Lilly and Company were worth $9,087,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Wealth Preservation Advisors LLC acquired a new stake in Eli Lilly and Company in the 1st quarter worth approximately $27,000. Sumitomo Mitsui Financial Group Inc. purchased a new position in Eli Lilly and Company in the second quarter valued at $27,000. Evolution Wealth Management Inc. purchased a new position in shares of Eli Lilly and Company during the 2nd quarter valued at approximately $29,000. Steph & Co. increased its stake in shares of Eli Lilly and Company by 290.0% during the third quarter. Steph & Co. now owns 39 shares of the company’s stock worth $30,000 after purchasing an additional 29 shares in the last quarter. Finally, Financial Gravity Companies Inc. purchased a new stake in shares of Eli Lilly and Company during the second quarter worth approximately $31,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $1,076.38 on Tuesday. The company has a 50-day moving average of $965.92 and a two-hundred day moving average of $833.56. The stock has a market cap of $1.02 trillion, a P/E ratio of 52.66, a PEG ratio of 1.08 and a beta of 0.37. The company has a current ratio of 1.55, a quick ratio of 1.24 and a debt-to-equity ratio of 1.71. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,111.99.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. The company had revenue of $17.60 billion during the quarter, compared to analysts’ expectations of $16.09 billion. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The business’s revenue for the quarter was up 53.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be issued a $1.73 dividend. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date is Friday, February 13th. This represents a $6.92 annualized dividend and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 29.35%.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Updated clinical data released for Lilly’s breast cancer programs and the EMBER‑3 Phase 3 update for imlunestrant indicate meaningful progress on oncology/gynecologic pipelines, supporting long‑term revenue diversification beyond obesity. Read More.
• Positive Sentiment: Bank of America and other sell‑side activity remain constructive: BofA keeps a Buy on LLY (with a modest PT change) and Goldman raised a price target, signaling continued analyst conviction that obesity launches will drive earnings growth into 2027 and beyond. Read More.
• Positive Sentiment: Media and pundit attention (Jim Cramer) is highlighting a major catalyst for Lilly—continued commercialization and new indications for weight‑loss and other specialty drugs—which can attract retail flows and support multiple expansion. Read More.
• Positive Sentiment: Deal chatter: reports that Lilly met French officials and related market moves (Abivax) suggest Lilly is actively pursuing partnerships/licensing that could add pipeline value if deals materialize. Read More.
• Positive Sentiment: Technical/momentum signals note LLY trading near its 52‑week high, which can attract momentum traders and algos ahead of upcoming earnings and regulatory milestones. Read More.
• Neutral Sentiment: Market commentary pieces (Zacks, JP Morgan preview) are drawing attention to Lilly’s valuation, guidance and upcoming catalysts; useful for framing expectations but not immediate price movers. Read More. Read More.
• Neutral Sentiment: Analyst notes on biotech peers (CRISPR Therapeutics) mention a partnership with Lilly; this validates Lilly’s external R&D strategy but is secondary to Lilly’s own drug launches. Read More.
• Negative Sentiment: Regulatory setback for Lilly’s obesity franchise competitively: the FDA approved Novo Nordisk’s Wegovy oral pill—the first daily oral obesity drug—giving Novo a first‑mover advantage in the oral obesity market and adding near‑term competitive pressure on Lilly’s oral candidate (orforglipron). This is the primary headwind in today’s tape. Read More.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Sanford C. Bernstein reiterated an “outperform” rating on shares of Eli Lilly and Company in a research report on Friday. Bank of America decreased their target price on Eli Lilly and Company from $1,286.00 to $1,268.00 and set a “buy” rating for the company in a report on Monday, December 15th. BMO Capital Markets set a $1,200.00 price target on Eli Lilly and Company in a research note on Thursday, December 4th. Loop Capital set a $950.00 price target on shares of Eli Lilly and Company in a research report on Monday, November 10th. Finally, Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Tuesday, October 14th. Four analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $1,155.36.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.